Allogene Therapeutics Balance Sheet Analysis

Assets, liabilities, and stockholders equity in billions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Allogene Therapeutics, Inc. (ALLO) - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Current Assets
Cash and Cash Equivalents0.080.080.060.170.830.530.46
Short-Term Investments0.220.370.460.280.640.000.00
Cash & Short-Term Investments0.290.450.520.460.830.530.46
Accounts Receivable0.000.000.000.010.010.000.00
Inventory0.000.000.000.000.000.000.00
Other Current Assets0.010.010.010.010.010.000.00
Total Current Assets0.300.460.530.470.850.540.47
Non-Current Assets
Property, Plant & Equipment (Net)0.130.160.200.180.160.040.04
Long-Term Investments0.080.000.080.370.210.000.00
Other Non-Current Assets0.030.020.020.020.010.010.00
Total Non-Current Assets0.250.180.290.580.380.120.31
Total Assets0.550.640.821.041.230.720.77
Current Liabilities
Accounts Payable0.010.010.010.010.010.010.02
Short-Term Debt0.010.000.000.000.000.000.00
Accrued Liabilities0.020.010.030.030.030.000.00
Deferred Revenue0.000.000.000.000.040.000.00
Other Current Liabilities0.000.000.000.000.040.020.00
Total Current Liabilities0.040.040.050.050.090.030.03
Non-Current Liabilities
Long-Term Debt0.080.090.100.070.050.050.03
Other Non-Current Liabilities0.010.010.010.000.000.000.01
Total Non-Current Liabilities0.090.090.100.080.050.060.04
Total Liabilities0.130.130.150.120.150.090.07
Stockholders' Equity
Common Stock0.000.000.000.000.000.000.00
Retained Earnings-1.82-1.56-1.23-0.90-0.65-0.40-0.21
Accumulated Other Comprehensive Income0.000.00-0.010.000.000.000.00
Additional Paid-in Capital2.242.081.911.821.731.020.91
Shares Outstanding0.210.170.140.140.000.000.00
Total Stockholders' Equity0.420.510.670.921.080.630.70
Total Liabilities & Equity0.550.640.821.051.230.720.77